119th Congress · introduced in the House · Feb 7, 2025
Medicare IVIG Access Enhancement Act of 2025
Official title from Congress.gov
Latest action (Feb 7, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 7, 2025)
Medicare IVIG Access Enhancement Act of 2025
This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Drug therapy · Health care costs and insurance · Health care coverage and access · Medicare · Neurological disorders
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
11 citations.
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$360,000
Spent on own lobbying
…D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Health Issues
$370,000
Spent on own lobbying
…D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 16, 2026 · issue area: Health Issues
$480,000
Spent on own lobbying
…D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…cess to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 18, 2026 · issue area: Health Issues
$470,000
Spent on own lobbying
…ccess to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Ac…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$450,000
Spent on own lobbying
…ccess to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 16, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
…cess to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
…cess to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 16, 2025 · issue area: Health Issues
$390,000
Spent on own lobbying
…ccess to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA, INC. · lobbying firm or registrant: HOGAN LOVELLS CADWALADER US LLP (FKA HOGAN LOVELLS US LLP)
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 15, 2025 · issue area: Health Issues
$80,000
Paid to lobbying firm
…cess to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRIFOLS SHARED SERVICES NORTH AMERICA INC · lobbying firm or registrant: GRIFOLS SHARED SERVICES NORTH AMERICA, INC.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 11, 2025 · issue area: Health Issues
$360,000
Spent on own lobbying
…cess to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusio…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing